Skip to search formSkip to main contentSkip to account menu

N-valproyl glycinamide

Known as: N-(Carbamoylmethyl)-2-Propylvaleramide, N-valproylglycinamide, VPGD cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Abstract The phenyl alcohol amides, DL-2-hydroxy-2-phenyl butyramide (CAS 52839-87-9), DL-3-hydroxy-3-phenyl pentanamide (CAS… 
2008
2008
Abstract DL-2-Hydroxy-2-phenyl butyramide (1, CAS 52839-87-9), DL-3-hydroxy-3-phenyl pentanamide (2, CAS 131802-69-2) and DL-4… 
Review
2006
Review
2006
In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their… 
Review
2004
Review
2004
Valproic acid (VPA) is one of four first-line antiepileptic drugs (AEDs) currently established in the long-term treatment of… 
Review
2004
Review
2004
Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of… 
Review
2002
Review
2002
Epilepsy is currently the most prevalent neurological disorder worldwide. Pharmacological therapy remains the cornerstone of… 
2001
2001
Summary:  Purpose: We sought to investigate the anticonvulsant activity of the new antiepileptic drug (AED), valrocemide or… 
Review
2001
Review
2001
Great progress has been made in the last 150 years in the pharmacological management of epilepsy, and, despite the increasing… 
2000
2000
AbstractPurpose. The purpose of this study was to evaluate the in vitro inhibitory potency of various amide analogues and…